New drug approvals in 2020


A number of new drugs for neurology and psychiatry are currently in review with regulatory authorities in the U.S. and Canada. The following summarizes some of the key therapies expected to be approved in 2020. Read More

FDA approves compassionate use of Ecstasy


The U.S. Food and Drug Administration has granted Expanded Access to methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), enabling some patients to undergo treatment before the drug is formally authorized. MDMA, known by the street names Ecstasy and Molly, was developed and patented by E. Merck (now EMD Serono) a century ago. It was used as an empathogen in psychotherapy during the 1970s but was labelled as a Schedule I controlled substance (no medical use) in 1985.

Read More